Diseases affecting posterior segment of the eye, such as age-related macular degeneration (AMD) are the leading cause of irreversible blindness worldwide.1, 2 The number of people living with macular degeneration is expected to reach 196 million worldwide by 2020 and increase to 288 million by 2040.3 In Germany, approximately 35,000 cases of neovascular AMD occur annually. The neovascular form of AMD (NV-AMD) is particularly responsible for the severe vision loss in 90% of the cases.4 The major challenge in delivering drug effectively to the posterior eye segment is to overcome elimination mechanisms (tear turn over, nasolachrymal drainage, systemic absorption, protein binding and enzyme degradation) and complex barriers (corneal barrier, blood-aqueous
